Company news

Rocket Pharmaceuticals, Inc. news in 2021

Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer

December 7, 2021

Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7: 30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

December 6, 2021

Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference

November 21, 2021

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

November 14, 2021

Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8: 30 a.m. ET to Present Updated Danon Disease Clinical Data

November 10, 2021

Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference

November 9, 2021

Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021

November 7, 2021

Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting

November 3, 2021

Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

November 2, 2021

Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 19, 2021

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 18, 2021

Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa

October 6, 2021

Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

September 29, 2021

Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021

September 13, 2021

Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021

September 9, 2021

Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer

September 6, 2021

Rocket Pharmaceuticals Announces $26.4 Million Private Placement

August 29, 2021

Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

August 15, 2021

Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

August 8, 2021

Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4: 30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights

August 2, 2021

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy

May 12, 2021

Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress

May 9, 2021

Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy

April 26, 2021

Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting

April 13, 2021

Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I

March 28, 2021

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

March 21, 2021

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

March 8, 2021

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

February 24, 2021

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

February 17, 2021

Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline

January 10, 2021

Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Calls in 2021

Decks in 2021